Alfred Ford Jr Sells 6,275 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Alfred Ford, Jr. sold 6,275 shares of the firm’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $24.09, for a total transaction of $151,164.75. Following the transaction, the insider directly owned 99,564 shares of the company’s stock, valued at $2,398,496.76. The trade was a 5.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Performance

Shares of KMTS traded up $0.21 during midday trading on Thursday, hitting $25.27. 184,867 shares of the company traded hands, compared to its average volume of 393,651. Kestra Medical Technologies, Ltd. has a 52 week low of $14.10 and a 52 week high of $30.00. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16. The firm has a 50 day moving average of $22.86 and a 200-day moving average of $22.54.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million for the quarter. As a group, sell-side analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current fiscal year.

Analyst Ratings Changes

KMTS has been the subject of a number of analyst reports. BTIG Research increased their price target on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Oppenheimer initiated coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They issued a “market perform” rating for the company. The Goldman Sachs Group reduced their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Wall Street Zen cut shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $27.83.

Institutional Trading of Kestra Medical Technologies

A number of hedge funds and other institutional investors have recently bought and sold shares of KMTS. Seven Grand Managers LLC purchased a new stake in shares of Kestra Medical Technologies during the fourth quarter valued at $2,652,000. Eventide Asset Management LLC grew its stake in Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after purchasing an additional 65,288 shares in the last quarter. Sei Investments Co. increased its holdings in Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after purchasing an additional 43,753 shares during the period. Summit Partners Public Asset Management LLC bought a new position in shares of Kestra Medical Technologies during the 4th quarter worth $9,282,000. Finally, UBS Group AG grew its position in shares of Kestra Medical Technologies by 34.9% during the 4th quarter. UBS Group AG now owns 270,058 shares of the company’s stock worth $7,162,000 after buying an additional 69,908 shares in the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.